Physician profile
Melissa Watcher
NPI 1538195797
$9,574.96
in general payments reported to CMS, 2019-2025
32 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,879 · 2020: $493 · 2021: $933 · 2022: $1,276 · 2023: $1,441 · 2024: $1,807 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,978 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,977.99 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,747.70 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $935.11 | 2019-2025 | |
| Pfizer INC. | $697.41 | 2019-2025 | |
| Janssen Biotech, INC. | $688.23 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Janssen Scientific Affairs, LLC | $562.12 | 2019-2022 | |
| Galderma Laboratories, L.P. | $497.77 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $480.88 | 2019-2025 | Libtayo, Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $389.07 | 2019-2025 | Cabtreo, Jublia |
| Leo Pharma INC. | $347.49 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $336.28 | 2020-2025 | |
| Ucb, INC. | $262.88 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $240.33 | 2019-2025 | |
| Dermavant Sciences, INC. | $220.83 | 2024 | Vtama |
| Incyte Corporation | $209.33 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $198.71 | 2019-2023 | Taltz, Olumiant |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $141.36 | 2023-2024 | Zoryve |
| Almirall LLC | $130.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.63 | 2022-2024 | Spevigo |
| Organon LLC | $49.41 | 2025 | Vtama |
| Journey Medical Corporation | $46.99 | 2025 | |
| Boston Scientific Corporation | $35.29 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Prugen, INC. Pharmaceuticals | $32.03 | 2019 | |
| Allergan, INC. | $29.32 | 2022 | |
| Biofrontera INC. | $28.49 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $27.71 | 2022 | |
| Amgen INC. | $24.80 | 2024 | Otezla |
| Verrica Pharmaceuticals INC. | $22.57 | 2024 | Ycanth |
| Sebela Pharmaceuticals INC. | $21.41 | 2022 | |
| Sandoz INC. | $20.62 | 2019 | |
| Celgene Corporation | $20.62 | 2019 | |
| Vyne Pharmaceuticals INC. | $18.39 | 2021 | |
| Mayne Pharma Commercial LLC | $6.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Watcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.